Search
forLearn
5 / 801 resultslearn panthenyl ethyl ether
learn PTD-DBM
learn PTT-6®
learn sh-Polypeptide-7
Research
5 / 1000+ results
research Scaffold-Assisted Artificial Hair Implantation in a Rat Model
Artificial hair implantation using scaffolds is possible and PHDPE is more biocompatible than ePTFE.
research Psychological assessment in 355 Chinese college students with androgenetic alopecia
Hair loss in Chinese college students leads to various psychological issues, so treatment should address both hair loss and mental health.
research Regulatory T Cells: the Many Faces of Foxp3
Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.
research Severe Acute Respiratory Syndrome Among Children
Children, especially teenagers, can get severe SARS-CoV infection with symptoms similar to adults, but they typically recover well with supportive care.
research Platelet Preparations for Use in Facial Rejuvenation and Wound Healing: A Critical Review of Current Literature
Platelet preparations generally show positive effects on wound healing and facial rejuvenation, but more thorough research is needed to confirm their effectiveness.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.